MIRNA QUANTIFICATION IN PATIENTS WITH SEPTIC SHOCK
Recruiting
Observational Study
Sepsis and Septic Shock
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 56 (estimated)
- Sponsor
- Insel Gruppe AG, University Hospital Bern · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Sepsis-induced immunosuppression (SIS) is a common complication in patients with septic shock. Reduced expression of Human leukocyte antigen isotype DR (HLA-DR) on circulating monocytes is a marker for SIS and correlates with risk of secondary infections and mortality. The miRSep study aims to improve the understanding of early microRNA (miRNA) mediated changes in HLA-DR on monocytes in patients w…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Septic shock:
* New onset (\<24h) of septic shock diagnosis according to Sepsis-3 definition
* (suspected) infection
* Vasopressors required to maintain mean arterial pressure ≥65mm Hg (despite adequate fluid resuscitation)
* Serum lactate level \> 2mmol/L
* Minimum age of 18 y…
Contacts
No contact information available.